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Abstract
Background: Multi drug resistant tuberculosis (MDR-TB) is an emerging challenge for TB control programs globally.
According to World health organization, 2012 report Ethiopia stands 15th out of the 27 high priority countries in the
world and 3rd in Africa. Updated knowledge of the magnitude of MDR-TB is so substantial to allocate resources,
and to address prevention and control measures. Therefore, the aim of this study was to assess the prevalence of
MDR-TB and associated risk factors in West Armachiho and Metema districts of North Gondar.
Methods: A cross-sectional study was conducted in West Armachiho and Metema districts between February 01
and June 25, 2014. A total of 124 consecutive smear positive pulmonary tuberculosis patients were included in the
study. Socio-demographic and possible risk factor data were collected using a semi-structured questionnaire. Drug
susceptibility testing was first performed for rifampicin using GeneXpert MTB/RIF. For those rifampicin resistant
strains, drug susceptibility testing was performed for both isoniazid and rifampicin to identify MDR-TB using the
proportional method on LJ media. Data were analyzed using statistical Package SPSS version 20; binary logistic
regression was used to assess the association. P-values < 0.05 were considered as statistically significant.
Results: Of 124 smear-positive pulmonary TB patients, 117 (94.4 %) were susceptible to Rifampicin, while 7 (5.7 %)
were confirmed to be resistant to Rifampicin and Isoniazid. The overall prevalence of MDR-TB was 5.7 % (2.3 %
among new cases and 13.9 % among previously treated cases). History of previous treatment (OR = 7, P = 0.025)
was significantly associated risk factor for MDR-TB.
Conclusion: The overall prevalence of MDR-TB was 5.7 % among cases at five health centers and a history of
previous treatment was found to be a risk factor for being infected by an MDR-TB strain. Therefore, maximizing
early case detection and treatment, strengthening TB infection control activities and proper implementation of
DOTS are recommended to reduce the burden of MDR-TB.
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Background
Tuberculosis (TB) remains a major global health problem.
In 2012, World health organization (WHO) estimated 8.6
million people developed TB and 1.3 million died from
the disease [1]. Even more, according WHO 2014 report,
the morbidity and mortality rate were increased by
400,000 and 200,000 cases, respectively, with reference to
the previous WHO report [2]. Besides both reports
presented that the mortality of the disease was predomin-
antly observed in human immunodeficiency virus (HIV)
co-infection, thus 320,000 (2012) and 360,000 (2013)
patients were died due to HIV co-infection. Tuberculosis
compound by the spread of multidrug resistant (MDR)
strains becomes a prime global concern, 450,000 and
480,000 multidrug resistant tuberculosis (MDR-TB) cases
were reported in 2012 and 2013 respectively. Based on
WHO 2014 report, the prevalence of MDR-TB among
new and previously treated cases was 3.5 % and 20.5 %
respectively. These estimates are essentially unchanged
from 2012 [1, 2].
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Emerging and spread of drug resistance TB has
encountered as a great challenge in Africa region,
Sub-Saharan Africa in particular. Information on the
extent of MDR-TB from Africa region is very limited,
probably due to poor laboratory facilities, poor surveil-
lance mechanisms and reporting procedures, outdated
databases and sub-optimal coverage of the infrequent
surveys. Sub-Saharan Africa stands the burden of both
very high TB incidence and the highest HIV prevalence
rates in the world, and represents 14 % of the global
burden of new MDR-TB cases [3].
Moreover, on the basis of WHO 2012 report, Ethiopia
stands 15th out of the 27 high priority countries in the
world and 3rd in Africa following South Africa and
Nigeria with (1600 and 480) among new and retreatment
cases respectively were MDR-TB cases [4]. According to
the drug resistance survey conducted nationwide, the
prevalence of MDR-TB was; 1.6 % in newly diagnosed
TB and 11.8 % among previously treated TB cases. The
country’s burden of MDR-TB in 2009 was estimated to
be 1500 (870–2600) and 420 (230–740) among new and
re-treatment cases respectively. Despite being a huge
global threat, access to treatment is very limited with
only 10 % of the estimated MDR-TB cases among noti-
fied TB cases in 2009 in the high MDR-TB countries
and 11 % globally were enrolled in treatment [5, 6].
In West Armachiho and Metema districts, information
regarding TB treatment interrupters, relapses, and
failure cases were not well documented. According to
the national comprehensive TB/HIV and Tuberculosis &
Leprosy guideline these are criteria for suspicion of
MDR-TB. Moreover, as to our knowledge, there are only
limited data regarding MDR-TB in this particular
study area. Therefore, current knowledge on the
prevalence of MDR is so substantial to provide useful
information on the implementation of standard
chemotherapy regimens designed and recommended
by WHO for tuberculosis patients who have or have
not been treated previously.
Moreover, drug resistance rate can also serve as a
useful parameter in the evaluation of the quality of
current and past chemotherapy program i.e. direct
observed treatment, short course (DOTS). Therefore,
understanding the drug susceptibility patterns of M.
tuberculosis (MTB) is very crucial to treat patients, to
decide health priorities, to allocate resources, to monitor
the emergency of resistance for planning effective use of
anti-TB drugs, to generate knowledge for health workers
working in the study area as well as will serve as a
preliminary information for health programmers to give
special attention and design a package in the national
TB control program that addresses such areas where
hundred to two hundred thousands of people are
employed in huge farms for the production of crops.
Methods
Study area, study design, participants and data collection
A cross-sectional study was conducted in West Armachiho
and Metema districts from Feburary 01 to June 25,
2014. A total of 124 smear positive patients were
consecutively enrolled through convenient sampling
technique. From those patients we gathered; socio-
demographic characteristics (gender, age, residence,
religion, occupation, marital status, income, ethnicity
and education status) and possible risk factors (HIV,
smoking, TB contact history, diabetes, fasting, history
of prison, BCG vaccination status). Besides from each pa-
tient, standard volumes of sputum sample were collected
after patients had given instructions accordingly.
Sputum decontamination, isolation, identification & drug
susceptibility testing
Smear positive sputum samples were re-confirmed
using Gene X-pert and decontamination and further
homogenization were done according to Petroff ’s
method. Isolates were identified by using typical col-
ony characteristics on Lowenstein-Jensen (LJ) media
and standard biochemical tests. Gene x-pert machine
was used to assess rifampicin (RIF) resistant strains,
after a while RIF resistant MTB isolates were tested
for isoniazid (INH) and RIF using the indirect pro-
portional method on LJ medium. The proportion
method calculates the proportion of resistant bacilli
present in a strain. Two appropriate dilution of the
bacilli, 10−2 and 10−4dilutions (undiluted = 106 to
108 CFU/ml), were inoculated on drug-containing and
drug-free media. Below a proportion (critical propor-
tion = 1 %), the strain was classified as sensitive;
otherwise classified as resistant. Patient’s HIV status
was collected from the TB unit register at TB clinic
of respective health facilities. Quality control was
done for gene x-pert (sample processing and probe
check) and LJ medium (standard strains of MTB
H37Rv-ATCC27294).
Data analysis
Data were entered and analyzed using SPSS version
20.0. Bivariate logistic regression analysis was used to
assess the association. P-values < 0.05 were considered
as statistically significant.
Ethical consideration
Ethical clearance was obtained from the School of Bio-
medical and Laboratory sciences, University of Gondar.
Written permission was obtained from North Gondar
Zone Health Department to West Armachiho and
Metema Woreda Health Offices and respective health
centers. Study participants were recruited after getting
written consent.
Mekonnen et al. BMC Infectious Diseases  (2015) 15:461 Page 2 of 6
Results
A total of 124 smear positive tuberculosis patients were
included from five different heath centers in West
Armachiho and Metema districts. The health centers were
Abderafi, Abirihajira, Metema Yohannes, Gendewuha and
Metema Hospital.
A majority, 80 (64.5 %) of the study participants
were males, the mean and median age of the study
subjects were 32 and 29 years respectively. Their age
ranges from16–75 years. Nearly half, 46 (48.1 %) were
in the age range of 26–35 year, while 37 (29.8 %)
were below 25 years old. Of the 124 study subjects,
66 (53.2 %) were urban inhabitants and 59 (47.6 %)
were farmers/day laborers. The majority, 116 (93.5 %)
of the study subjects were Christians by religion while
the rest 8 (6.5 %) were Muslims. More than half, 64
(51.6 %) were illiterate. More than half of new and
previously treated cases were males (Table 1).
The proportion of smear positive tuberculosis cases in
each health facilities were as follows: Abderafi 49
(39.5 %), Metema Hospital, 34 (29.8 %), Abirihajira 21
(12.9 %), Metema Yohannes 16 (12.9 %) and Gendewuha
4 (3.2 %).
Prevalence of Multi- drug resistant tuberculosis (MDR-TB)
Sputum samples of the 124 smear positive tubercu-
losis patients were tested for MDR-TB by using
Gene-Xpert MTB/RIF technique and conventional
solid culture, The overall prevalence of MDR-TB was
7 (5.6 %, 95 % CI; 2.4–10.5 %) and prevalence of
MDR-TB among new smear positive TB cases was 2
(2.3 %, 95 % CI; 0–5.9 %) and among previously
treated smear positive TB cases 5 (13.9 %, 95 % CI;
2.9–25.7 %). Of the 26 who were reported to have
been cured with prior treatment, 1 (3.8 %) and
from10 who were reported to have failed or defaulted
from prior treatment, 4 (40 %) were relapsed MDR-
TB cases. Among 41 patients whose occupation was
farmer/daily laborer, 2 (4.9 %) had primary MDR-TB;
of 47 whose occupation was other than farmer/day
laborer none (0.0 %) had primary MDR-TB. The
majority of confirmed MDR-TB subjects were males 6
(85.7 %) and two of the confirmed MDR cases were
co-infected with HIV (28.6 %) while, the other five
were sero-negative.
Among the five health facilities, MDR-TB cases were
obtained from Abderafi health center and Metema
District Hospital. Three MDR-TB cases (one from new
smear positive study subjects and two from retreatment
cases) were identified from Abderafi health center. The
other four MDR-TB cases (one from new smear positive
study subjects and three from retreatment cases) were
identified from Metema hospital.
Table 1 Socio-demographic characteristics of TB patients West
Armachiho and Metema districts, Northwest Ethiopia February
01 to June 25, 2014
Variable Total TB cases
(N = 124)
New active TB
cases (N = 88)
Retreatment TB
cases (N = 36)
Age group in years
≤25 37 (29.8 %) 31 (35.2) 6 (16.7)
26–35 57 (46 %) 38 (43.2) 19 (52.8)
36–45 16 (12.9) 11 (12.5) 5 (13.9)
≥46 14 (11.3) 8 (9.1) 6 (16.7)
Gender
Male 80 (64.5) 53 (60.2) 27 (75)
Female 44 (35.5) 35 (39.8) 9 (25)
Resident
Urban 66 (53.2) 47 (53.4) 19 (52.8)




59 (47.6) 41 (46.6) 18 (50)
House wife 28 (22.6) 21 (23.9) 7 (19.4)
Government
employee
8 (6.5) 8 (9.1) 0
Merchant 16 (12.9) 13 (14.8) 3 (8.3)
Driver 5 (4) 1 (1.1) 4 (11.1)
Student 8 (6.5) 4 (4.5) 4 (11.1)
Income/month:
<500 birr 39 (31.5) 29 (33) 10 (27.8)
500 birr - 999 birr 55 (44.4) 39 (44.3) 16 (44.4)
≥1000 birr 25 (20.2) 16 (18.2) 9 (25)
No means of income 5 (4) 4 (4.5) 1 (2.8)
Religion:
Christian 116 (93.5) 82 (93.2) 34 (94.4)
Muslim 8 (6.5) 6 (6.8) 2 (5.6)
Ethnicity:
Amhara 102 (82.3) 77 (87.5) 25 (69.4)
Tigre 22 (17.7) 11 (12.5) 11 (30.6)
Educational status:
Illiterate 64 (51.6) 42 (47.7) 22 (61.1)
Primary school 36 (29.0) 26 (29.5) 10 (27.8)
Secondary school 17 (13.7) 14 (15.9) 3 (8.3)
Diploma and above 7 (5.6) 6 (6.8) 1 (2.8)
Marital status:
Married 62 (50) 44 (50) 18 (50)
Un married 45 (36.3) 35 (39.8) 10 (27.8)
Widowed 5 (4) 4 (4.5 %) 1 (2.8)
Divorced 12 (9.7) 5 (5.7) 7 (19.4)
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Rifampicin resistant Non-MDR-TB
Sputum samples of 124 smear positive pulmonary TB
cases were processed using Gene-X pert MTB/RIF for
detection of MTB and identification of RIF resistant
strain. Of these only seven smears positive cases were
found to be RIF resistant. Sputum samples of RIF resist-
ant cases were further diagnosed with LJ medium for
growth of MTB and detection of INH resistance as well
as confirmation of RIF resistant strain. The result
showed RIF resistant non-MDR-TB isolates were not ob-
served from all RIF resistant isolates that were detected
by Gene-X pert MTB/RIF for drug susceptibility testing.
All seven RIF resistant isolates were found to be MDR-
TB cases.
Risk factors for MDR-TB
The relationship between individual exposure variables
and MDR-TB status is shown in Table 2. Association be-
tween potential exposure variables and MDR-TB were
analyzed. Socio-demographic determinants such as age,
sex, residence, occupation, income, religion, fasting,
ethnicity, educational status, marital status, and factors
such as contact history, history of imprisonment, number
of rooms in the house, family number in the household,
rooms for sleeping, number of windows and use of
substances like cigarette smoking and other clinical
characteristics such as, diabetes, history of previous
anti-TB treatment, outcome of previous treatment,
BCG vaccination, HIV status, history of taking illegal
anti-TB treatment were assessed.
All the variables that were considered important were
entered into the binary logistic regression models and
analysis showed there were significant association
between MDR-TB and history of previous anti-TB treat-
ment (OR: 7, 95 % CI = 1. 2–37.6, P = 0. 025). However,
there were no significant association between other
variables and MDR-TB. After adjustment for interactions
among the independent variables with the binary
regression model; analysis also showed there were no
significant association between independent variables
and prevalence of MDR-TB (P > 0.05) with each factor
other than previous treatment history.
Discussion
The burden of MDR-TB becomes increasing in alarming
pace with function of time particularly in the poorest
countries. Before 20 years ago, reports showed that the
prevalence of MDR-TB was almost nil or 1 % in different
parts of Ethiopia [7–9]. Though, nowadays high pro-
portion of MDR-TB were notified within the country
[10, 11]. It is well understood that bacterial and environ-
mental factors play a great role in the spread of MDR-TB.
Within the population MTB, spontaneous mutation in
genes responsible for drug resistance for all first line and
Table 2 Factors associated with the MDR-TB status among
Pulmonary TB cases, West Armachiho and Metema districts,
Northwest Ethiopia, February 01 to June 25, 2014






≤25 1 36 2.77 (0.16, 47.56) 0.483
26–35 4 53 1.02 (0.11,9.90) 0.987
36–45 1 15 1.15 (0.07,20.34) 0.922
≥46 1 13 1
Gender
Male 6 79 3.49 (0.41, 29.9 4) 0.255
Female 1 43 1
Resident
Rural 4 54 1.56 (0.33, 7.26) 0.574




4 55 1.50 (0.32, 7.01) 0.604
Other 3 62 1
Ethnicity:
Tigre 3 19 3.87 (0.80,18.70) 0.092
Amhara 4 98 1
Educational status:
Illiterate 2 62 5.17 (0.41, 65.68) 0.206
Primary school 3 33 1.83 (0.16,20.71) 0.624
Secondary school 1 16 2.67 (0.14,49.76) 0.511
Diploma and above 1 6 1
Fasting
Yes 3 73 0.45 (0.10, 2.12) 0.313
No 4 44 1
History of smoking
Yes 2 33 1.02 (0.19, 5.51) 0.983
No 5 84 1
BCG vaccination
Yes 1 27 0.71 (0.13, 3.89) 0.698
No 6 90 1
History of previous
treatment
Yes 5 31 6.94 (1.28, 37.60) 0.025
No 2 86 1
HIV status
Yes 2 26 1.40 (0.25, 7.64) 0.698
No 5 91 1
History of prison
Yes 1 17 0.98 (0.11, 8.66) 0.986
No 6 100 1
Note that: N number of subjects, OR Odds Ratio
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some second line drugs, thus scenarios are highly
pronounced by misuse of drugs results in rapid selection
of drug resistant mutants [12].
The present study demonstrated MDR-TB is a serious
issue of concern in the study area; hence the overall
prevalence of MDR-TB was 5.6 % (95 % CI, 2.4–10.5 %).
Which is comparable with previous reports from north-
western Ethiopia and national wide survey in Ethiopia
[6, 13, 14]. On the other hand, it is lower than finding
from Jimma and Bahirdar [10, 15]. The possible explan-
ation for this difference could be due the fact that this
study was conducted at the site where TB patients less
likely served for medical attention and presumably they
have accustomed to visit nearby and relatively advanced
health institutions. Besides in previous reports the study
population was presumptive MDR-TB patients, whereas
in this study only smear positive TB cases were included.
Furthermore, in this finding the prevalence of MDR-
TB among new and previously treated cases was respect-
ively 2.3 % and 13.9 %. Which is consistent with previ-
ous documented data [13, 14, 16]. Many of the research
findings advocated that MDR-TB are frequently identi-
fied in patients with history of TB treatment [6, 13, 14],
which is also evidenced in this study. In fact, prior treat-
ment creates opportunity for resistance MTB mutant to
dominant and results challenging in the management of
cases [12]. Emergence of new cases with MDR-TB has
frequently related with close contact with known cases,
facilitated by overcrowding [17]. Likewise, the present
study showed that all of new MDR-TB cases were
farmers and day laborers. The truth is a large number of
people share the same house or camp for sheltering for
the production of crops in the study area, which could
be aggravate the issue of concern.
Moreover, this study was aimed to assess associated risk
factors of acquisition of MDR-TB. History of previous
treatment was the only significantly associated risk factor
with MDR-TB (OR: 7, 95 % CI = 1.28–37.6, P = 0.02),
which shows agreement with previous published reports
[12, 14, 17]. This is due to the fact that prior anti-TB ex-
posure provides only to suppress the growth of susceptible
bacilli, but on the other side, it could permit suitable
circumstances for the multiplication of pre-existing drug
resistant mutants [12].
Even though, this study explored that history of treat-
ment is the only risk factors for acquisition of MDR
strains, however, several evidences claimed that factors
including HIV/AIDS, overcrowding, smoking, opportun-
istic infection, lack of compliance with DOTS program,
are also the potential risk factors attributes MDR-TB in-
fection [15, 18–20]. In the recent time, global MDR-TB
control programs have planned by considering the above
factors, along with the highest level of compliance with
guidelines (early case detection, complete treatment,
administrative, environmental, or engineering controls
and personal respiratory protection) [3, 12]. It is well
acknowledged that DOTS strategy is the best weapon to
dismantle the spread of MDR-TB [3]. Despite the fact
that we have observed poor implementation of DOTS in
the study area, hence it requires political commitment,
sustainable budget allocation, effective drug supply and
management system, and continuous monitoring and
evaluation system.
Conclusion
We report an overall prevalence of MDR-TB of 5.7 %
among all cases, with the prevalence of MDR-TB among
previously treated cases being 13.9 % and among new
cases only 2.3 %. History of previous anti TB treatment
was the only statistically significant risk factor for MDR-
TB. Therefore, actions should be directed to improve the
DOTS program and to maximize diagnostic laboratory
facilities.
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